Sarepta announced that screening is underway in Study SRP-9003-301. Also known as EMERGENE, Study 9003-301 is a Phase 3, multi-national, open-label study of SRP-9003 for the treatment of limb-girdle muscular dystrophy Type 2E, or beta sarcoglycanopathy. EMERGENE will enroll 15 participants, aged 4 and older, and uses commercially representative process SRP-9003 material.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SRPT:
- Sarepta reports preliminary FY23 net product revenue $1.145B
- Regenxbio: Sarepta granted summary judgment on invalidity in patent suit
- Arcellx named as 2024 Top Pick, added to Conviction List at Needham
- Sarepta submits efficacy supplement to expand Elevidys label
- Sarepta price target lowered to $130 from $160 at Mizuho
